VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Immunotherapy for Castration-Resistant Prostate Cancer

Panelists: Mark S. Austenfeld, MD, Kansas City Urology Care; Raoul S. Concepcion, MD, Urology Associates, PC; E. David Crawford, MD, University of Colorado;
Published: Tuesday, Sep 18, 2012


The role of immunotherapy for men with castration-resistant prostate cancer (CRPC) is an area that has garnered a great deal of discussion among physicians. E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC.

Crawford foresees a large paradigm shift in the future for urologists treating CRPC. Multiple new therapeutics, which are easily given by urologists, are rapidly becoming available, such as the immunotherapy sipuleucel-T and the investigational agent radium-223, which Crawford describes as a game changer. Recently approved agents include abiraterone acetate and enzalutamide with TAK-700 (orteronel) and lyase inhibitors rapidly approaching in the development pipeline.

The many different mechanisms of actions for these agents make combinations a viable option. Crawford believes the combination of enzalutamide and abiraterone acetate could result in a game changing powerful option.
Slider Left
Slider Right


The role of immunotherapy for men with castration-resistant prostate cancer (CRPC) is an area that has garnered a great deal of discussion among physicians. E. David Crawford, MD, agrees with the NCCN guidelines, which suggest that sipuleucel-T (Provenge) should be the first-line choice for minimally or asymptomatic CRPC.

Crawford foresees a large paradigm shift in the future for urologists treating CRPC. Multiple new therapeutics, which are easily given by urologists, are rapidly becoming available, such as the immunotherapy sipuleucel-T and the investigational agent radium-223, which Crawford describes as a game changer. Recently approved agents include abiraterone acetate and enzalutamide with TAK-700 (orteronel) and lyase inhibitors rapidly approaching in the development pipeline.

The many different mechanisms of actions for these agents make combinations a viable option. Crawford believes the combination of enzalutamide and abiraterone acetate could result in a game changing powerful option.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x